Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2741 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi 2019-06-04
Verdel Instruments–Longwall Venture Partners: investment, 201905 seed financing round totalling £230k incl £100k from Longwall Ventures 2019-05-30
Verdel Instruments–SEVERAL: investment, 201905 seed financing round £230k from Longwall Venture Partners + Innovate UK 2019-05-30
Verdel Instruments–United Kingdom (govt): investment, 201905 seed financing round totalling £230k incl investor Innovate UK 2019-05-30
Oxford BioMedica–Novo Group: investment, 201905–201906 investment £45.3m + optional £8.2m with 6.6m+1.2m new shares at £6.9/share 2019-05-28
JnJ–Owlstone: breath analyser, 201905– collab developm breath-based test for early detection of pulmonary hypertension with Actelion 2019-05-20
LifeArc–CPPIB: pembrolizumab, 201905 acquisition of portion of Keytruda royalty interests for $1.297b by CPPIB Credit Europe Sàrl 2019-05-20
Storm Therapeutics–Cambridge Innovation Capital: investment, 201905 financing round Series A extension totalling £14m incl existing investor CIC 2019-05-20
Storm Therapeutics–IP Group: investment, 201905 financing Series A extension totalling £14m incl existing investor IP Group 2019-05-20
Storm Therapeutics–Merck (DE): investment, 201905 financing round Series A extension totalling £14m incl existing investor M Ventures 2019-05-20
Storm Therapeutics–Otsuka: investment, 201905 financing Series A extension totalling £14m incl existing investor Taiho Ventures 2019-05-20
Storm Therapeutics–Pfizer: investment, 201905 financing round Series A extension totalling £14m incl existing investor Pfizer Ventures 2019-05-20
Storm Therapeutics–Seroba: investment, 201905 financing round Series A extension totalling £14m incl new investor Seroba Life Sciences 2019-05-20
Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS 2019-05-20
Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders 2019-05-15
United Kingdom (govt)–Congenica: bioinformatics, 201905 supply existent processing of samples for 100,000 Genomes Project for Genomics England 2019-05-14
Philogen–Consilium: public relations, 201905 service existent by CSC 2019-05-13
TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA 2019-05-13
OMass–DyNAbind: drug discovery technology, 201905 collab existent with OMass Therapeutics 2019-05-07
Sosei–DyNAbind: drug discovery technology, 201905 collab existent with Sosei Heptares 2019-05-07
AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO 2019-05-02
Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson 2019-05-02
Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif 2019-04-30
Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq 2019-04-30
Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures 2019-04-30
Enzyre–Optimum Strategic Communications: public relations, 201904 service existent by Optimum 2019-04-30
Poseida Therapeutics–Malin Corp: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Malin Corp 2019-04-22
Boehringer–PureTech Health: cancer immunotherapy, 201904– colllab research up to $226m + royalties using lymphatic targeting platform for I-O drugs 2019-04-17
Catalent–Leonard Green & Partners: investment, 201904– up to $1b convertible preferred stock with $650m issued 2019-04-15
Paragon Bioservices–Catalent: investment, 201904– acquisition 100% for $1.2b in cash on cash-free + debt-free basis 2019-04-15
AgomAb Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif für UK + RoW 2019-04-03
Cambridge Innovation Capital–SEVERAL: investment, 201904 financing round £150m with Univ Cambridge as cornerstone investor 2019-04-01
Cambridge Innovation Capital–Univ Cambridge: investment, 201904 financing round totalling £150m incl cornerstone investor Univ Cambridge 2019-04-01
Digital China Health–Congenica: bioinformatics, 201904 collab existent DCH is commercial partner for Sapientia s/w in China 2019-04-01
Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health 2019-04-01
Karuna–SEVERAL: investment, 201903–201904 financing round Series B $80m led by ARCH Venture Partners incl $5m debt conversion 2019-04-01
Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust 2019-04-01
Mogrify–United Kingdom (govt): grant, 201904 SBRI Healthcare funding for developm of cell therapy for osteoarthritis 2019-04-01
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Inivata–Consilium: public relations, 201903 service existent by CSC 2019-03-28
Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors 2019-03-28
Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study 2019-03-28
Exscientia–Edelman: public relations, 201803 service existent by Edelman PR 2019-03-22
Celgene–Exscientia: drug discovery software, 201903–202203 collab $25m upfront + milestones + royalties 3y AI drug discovery partnership 2019-03-21
United Kingdom (govt)–Cambridge Cancer Genomics: personalised immuno-oncology, 201903– collab long-term of Genomics England + CCG.ai 2019-03-21
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
NeoPhore–Optimum Strategic Communications: public relations, 201903 service existent by Optimum 2019-03-20
Oncimmune–Consilium: public relations, 201903 service existent by CSC 2019-03-19
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Mogrify–United Kingdom (govt): grant, 201903 Innovate UK funding £420k to use big data analysis to advance cell therapies 2019-03-18
Metrion Biosciences–o2h: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Metrion Biosciences–SEVERAL: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectors by MolMed for three new indications 2019-03-13
Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors 2019-03-12
AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies 2019-03-11
Univ Manchester–Owslstone: breath analysis technology, 201903– collab developm asthma diagnostic with £250k grant from Innovate UK + Asthma UK 2019-03-07
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation 2019-02-28
CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio 2019-02-27
MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management 2019-02-27
MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc 2019-02-27
MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors 2019-02-27
MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors 2019-02-27
MeiraGTx–SEVERAL: investment, 201902 private placement $80m with 5.8m ordinary shares at $13.8/share led by JJDC Inc 2019-02-27
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Mobidiag–Consilium: public relations, 201902 service existent by CSC 2019-02-25
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
Mogrify–24Haymarket: investment, 201902 seed financing round totalling $3.7m incl co-investor 24Haymarket 2019-02-20
Mogrify–Ahren Innovation Capital: investment, 201902 seed financing round totalling $3.7m incl existing + lead investor Ahren Innovation Capital 2019-02-20
Mogrify–PERSON: investment, 201902 seed financing round totalling $3.7m incl co-investor Darrin M Disley 2019-02-20
Mogrify–SEVERAL: investment, 201902 seed financing round $3.7m led by Ahren Innovation Capital + incl 24Haymarket + Darrin Disley 2019-02-20
Mogrify–Zyme Communications: public relations, 201902 service existent by Zyme 2019-02-20
Sphere Fluidics–Oxford Genetics: automated microfluidic system for gene editing, 201902– collab with SF + OG + Univ Edinburgh + Twist Bioscience 2019-02-18
Sygnature Discovery–BioStrata: public relations, 201902 service existent by BioStrata 2019-02-15
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Consilium: public relations, 201902 service existent by CSC 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Pathios Therapeutics–Sygnature Discovery: drug discovery services, 201902– collab service discovery for GPCR target in autoimmune diseases + cancer 2019-02-07
United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS 2019-02-04
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
JnJ–MeiraGTx: gene therapy, 201901– collab r+d + license ww excl $100m upfront + milestones + funding + 20% royalties for inherited retinals diases 2019-01-31
Sphere Fluidics–24Haymarket: investment, 201901–201906 financing round totalling $4.8m in 2 tranches incl co-investor 24Haymarket Ltd 2019-01-29
Sphere Fluidics–Greenwood Way Capital: investment, 201901–201906 financing round totalling $4.8m in 2 tranches incl $4.3m from Greenwood Way Capital 2019-01-29
Sphere Fluidics–OTIF: investment, 201901–201906 financing round totalling $4.8m incl co-investor Oxford Technology & Innovations EIS Fund 2019-01-29
Sphere Fluidics–SEVERAL: investment, 201901–201906 financing round $4.8m (£3.7m) in 2 tranches led by Greenwood Way Capital with $4.3m 2019-01-29
Horizon Discovery–Rutgers Univ: gene editing technology, 201901– collab strategic developm + excl license option for base editing technology 2019-01-28
Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group 2019-01-22
Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital 2019-01-22
Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals 2019-01-22
Sphere Fluidics–Peak Analysis and Automation: lab automation technology, 201901– collab integration of S-LAB plate handler with Cyto-Mine system 2019-01-15
ATUM–Solentim: cell line development technology, 201901– collab product integration of VIPS hardware + Leap-In Transposase expression technology 2019-01-14
Solentim–Sciad Communications: public relations, 201901 service existent by Sciad 2019-01-14
Chronomics–SEVERAL: investment, 201901 seed financing round £1.12m from Anthemis + SOSV 2019-01-10
AstraZeneca–Aptamer Group: aptamer drug conjugates, 201901– collab research to enable drug delivery to the kidney 2019-01-07
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top